Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa in vitro.
The uptake of ovalbumin-conjugated starch microparticles (OVA-MP) was studied after application to porcine respiratory nasal mucosa in vitro. Nasal mucosa from freshly slaughtered pigs was mounted in horizontal Ussing chambers, which permit monitoring of the viability of the tissue exposed to microparticles and ensure that the microparticles are deposited on the mucosa. The antigen-conjugated starch microparticles have previously been shown to produce strong mucosal, cellular and systemic immune responses to conjugated model antigens following oral administration. Intranasal administration of vaccines for mucosal immunisation is an interesting alternative to oral administration, since nasal delivery systems generally require lower doses of antigen and the site of application is better suited for protection against air-borne antigens. Most of a nasally administered dose is deposited on the surface of the respiratory area of the nasal mucosa. It is therefore important to examine whether the microparticles are taken up in this area and, if so, by which cell type. Confocal laser scanning microscopy and transmission electron microscopy (TEM) of the nasal tissue both showed intracellular OVA-MP in non-ciliated epithelial cells after 45 min' incubation. The morphology of the cells in the TEM preparations did not support the presence of either M cells (specialised antigen sampling cells) or adjacent lymphocytes. Anticytokeratin-18 (Ac18) was used as a potential M cell marker. However, there was no indication of Ac18 binding to M cells, but it did bind to mucus-producing cells in the respiratory nasal mucosa. In conclusion, OVA-MP were taken up intracellularly by non-ciliated epithelial cells in the nasal respiratory mucosa of pigs, in vitro.
Osth
Karin
K
Department of Pharmacy, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden.
Strindelius
Lena
L
Larhed
Agneta
A
Ahlander
Anders
A
Roomans
Godfried M
GM
Sjöholm
Ingvar
I
Björk
Erik
E
D000818:Animals; D002214:Capsules; D002463:Cell Membrane Permeability / Q000502:physiology; D002626:Chemistry, Pharmaceutical; D066298:In Vitro Techniques; D009297:Nasal Mucosa / Q000378:metabolism* / Q000648:ultrastructure; D010047:Ovalbumin / Q000493:pharmacokinetics*; D013213:Starch / Q000493:pharmacokinetics*; D013552:Swine
D002214:Capsules; D013213:Starch; D010047:Ovalbumin